These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26806585)
1. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Al Malki MM; Horowitz M; Handgretinger R; Leung W; Roy DC; Huang XJ; Fuchs E; Locatelli F; Blaise D; Mineishi S; Martelli M; Miller J; June C; Ai HS; Luznik L; Mavilio D; Lugli E; van den Brink MRM; Champlin RE; Ciurea SO Biol Blood Marrow Transplant; 2016 Apr; 22(4):594-604. PubMed ID: 26806585 [TBL] [Abstract][Full Text] [Related]
2. Recent developments in HLA-haploidentical transplantations. Showel M; Fuchs EJ Best Pract Res Clin Haematol; 2015; 28(2-3):141-6. PubMed ID: 26590771 [TBL] [Abstract][Full Text] [Related]
3. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745 [TBL] [Abstract][Full Text] [Related]
4. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
6. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Munchel AT; Kasamon YL; Fuchs EJ Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089 [TBL] [Abstract][Full Text] [Related]
7. Advances in haploidentical stem cell transplantation for hematologic malignancies. Montoro J; Sanz J; Sanz GF; Sanz MA Leuk Lymphoma; 2016 Aug; 57(8):1766-75. PubMed ID: 27424663 [TBL] [Abstract][Full Text] [Related]
8. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668 [TBL] [Abstract][Full Text] [Related]
9. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Kanakry CG; Bakoyannis G; Perkins SM; McCurdy SR; Vulic A; Warren EH; Daguindau E; Olmsted T; Mumaw C; Towlerton AMH; Cooke KR; O'Donnell PV; Symons HJ; Paczesny S; Luznik L Haematologica; 2017 May; 102(5):932-940. PubMed ID: 28126963 [TBL] [Abstract][Full Text] [Related]
11. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Fuchs EJ Bone Marrow Transplant; 2015 Jun; 50 Suppl 2(0 2):S31-6. PubMed ID: 26039204 [TBL] [Abstract][Full Text] [Related]
12. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379 [TBL] [Abstract][Full Text] [Related]
13. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation. Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124 [TBL] [Abstract][Full Text] [Related]
14. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903 [TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide. Muñiz P; Kwon M; Carbonell D; Chicano M; Bailén R; Oarbeascoa G; Suárez-González J; Andrés-Zayas C; Menárguez J; Dorado N; Gómez-Centurión I; Anguita J; Díez-Martín JL; Martínez-Laperche C; Buño I Front Immunol; 2021; 12():642087. PubMed ID: 33841425 [TBL] [Abstract][Full Text] [Related]
16. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related]
17. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study. Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Castagna L; Crocchiolo R; Furst S; Bramanti S; El Cheikh J; Sarina B; Granata A; Mauro E; Faucher C; Mohty B; Harbi S; Chabannon C; Carlo-Stella C; Santoro A; Blaise D Biol Blood Marrow Transplant; 2014 May; 20(5):724-9. PubMed ID: 24530426 [TBL] [Abstract][Full Text] [Related]
19. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
20. Haploidentical transplantation for hematologic malignancies: where do we stand? Fuchs EJ Hematology Am Soc Hematol Educ Program; 2012; 2012():230-6. PubMed ID: 23233586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]